Literature DB >> 7014043

Combined captopril and spironolactone treatment in Conn's syndrome with renal impairment and refractory hypertension.

A B Atkinson, J J Brown, D L Davies, A F Lever, J I Robertson.   

Abstract

Spironolactone alone in full dosage failed to correct hypertension in a patient with Conn's syndrome and renal impairment, although the previously increased total exchangeable sodium fell to normal and the previously suppressed plasma angiotensin II did not rise above the normal range. Addition of the converting enzyme inhibitor captopril reduced plasma angiotensin II to very low levels, with a slight further fall in exchangeable sodium. Blood pressure was well controlled. Because hypertension in Conn's syndrome resistant to spironolactone usually also responds poorly to removal of the adenoma, and is difficult to treat with conventional hypotensive agents, the combination of a converting enzyme inhibitor with a potassium conserving diuretic is worthy of trial in such cases.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7014043     DOI: 10.1111/j.1365-2265.1981.tb00371.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  2 in total

Review 1.  [Modern pharmacological aspects of hyperaldosteronism therapy].

Authors:  M Quinkler; M Reincke
Journal:  Internist (Berl)       Date:  2006-09       Impact factor: 0.743

2.  Captopril before and after spironolactone therapy in primary aldosteronism. Pathogenetic and therapeutical aspects.

Authors:  M Stimpel; W Vetter; H Groth; P Greminger; H Vetter
Journal:  Klin Wochenschr       Date:  1985-04-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.